Increased levels of urinary leukotriene E4 in children with severe atopic eczema/dermatitis syndrome

被引:13
作者
Oymar, K
Aksnes, L
机构
[1] Cent Hosp Rogaland, Dept Pediat, N-4068 Stavanger, Norway
[2] Univ Bergen, Dept Clin & Mol Med, Div Pediat, Bergen, Norway
关键词
atopic eczema; dermatitis syndrome; atopy; children; leukotriene E4; leukotrienes;
D O I
10.1111/j.1398-9995.2005.00658.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Leukotrienes are thought to play a role in the pathogenesis of atopic eczema/dermatitis syndrome (AEDS). Urinary leukotriene E4 (U-LTE4) is a marker of whole-body cysteinyl-leukotriene production. Aims of the study: To evaluate the role of leukotrienes in children with AEDS by measuring levels of U-LTE4, and to evaluate whether levels of U-LTE4 may reflect disease activity and allergic sensitization in AEDS. Methods: U-LTE4 was measured by enzyme-linked immunosorbent assay in 87 children with mild (n = 32), moderate (n = 34) and severe (n = 21) AEDS, as well as in 72 nonatopic healthy controls. Fifty-eight of the children with AEDS were sentitized to common allergens, and 29 were not. Results: Levels of U-LTE4 were higher in children with severe AEDS (140; 66-166 mug/mmol creatinine, median; quartiles) than in controls (52; 30-90, P < 0.05), whereas levels of U-LTE4 in moderate and mild disease were similar to controls. U-LTE4 levels were similar in children with or without sensitization to common allergens, but severe AEDS children with sensitization had higher levels of U-LTE4 than those without sensitization. Conclusion: The results suggest a role for leukotrienes in the pathogenesis of severe AEDS, and may support a role for leukotriene-antagonists in the treatment of this disorder. Levels of U-LTE4 may reflect the disease severity and sensitization to allergens in AEDS.
引用
收藏
页码:86 / 89
页数:4
相关论文
共 15 条
[1]   Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status [J].
Adamek-Guzik, T ;
Guzik, TJ ;
Czerniawska-Mysik, G ;
Korpanty, G ;
Mastalerz, L ;
Radwan, J ;
Szczeklik, A .
ALLERGY, 2002, 57 (08) :732-736
[2]   ENHANCED SYNTHESIS OF CYSTEINYL LEUKOTRIENES IN ATOPIC-DERMATITIS [J].
FAULER, J ;
NEUMANN, C ;
TSIKAS, D ;
FROLICH, JC .
BRITISH JOURNAL OF DERMATOLOGY, 1993, 128 (06) :627-630
[3]  
HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44
[4]   Increased urinary leukotriene E4 excretion in patients with atopic dermatitis [J].
Hishinuma, T ;
Suzuki, N ;
Aiba, S ;
Tagami, H ;
Mizugaki, M .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (01) :19-23
[5]   Leukotriene receptor antagonists -: A novel therapeutic approach in atopic dermatitis? [J].
Kägi, MK .
DERMATOLOGY, 2001, 203 (04) :280-283
[6]   Chemical mediators in atopic dermatitis:: Involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis [J].
Koro, O ;
Furutani, K ;
Hide, M ;
Yamada, S ;
Yamamoto, S .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (04) :663-670
[7]   EOSINOPHILS IN ATOPIC-DERMATITIS [J].
LEIFERMAN, KM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (06) :1310-1317
[8]   Atopic dermatitis [J].
Leung, DYM ;
Bieber, T .
LANCET, 2003, 361 (9352) :151-160
[9]   Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity [J].
Oymar, K ;
Bjerknes, R .
ALLERGY, 2000, 55 (10) :964-968
[10]  
RAJKA G, 1989, ACTA DERM-VENEREOL, P13